BRL Medicine Completes New Round of Financing to Accelerate Core Product Registration and Industrialization
2026-11-09
BRL-303 Receives IND Approval for Systemic Sclerosis and Is Included in CDE’s “Care Plan”
2026-10-09
BRL Medicine’s BRL-101 Pivotal Trial Meets Primary Endpoint
2026-08-25
6-Year Follow-Up Confirms Durable Efficacy of BRL-101 in β‑Thalassemia
2026-07-22
World's First! BRL Medicin's BCMA UCAR-T Successfully Treats Neuromyelitis Optica Spectrum Disorder
2025-10-11
The First Patient Treated with BRL Medicine’s BRL-201 Therapy Achieves Over 5 Years of Cancer-Free Survival
2025-09-17